Compare Merck & Co., Inc. (MRK) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs TKO Group Holdings Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while TKO Group Holdings Inc trades at $191.08 (market cap $14.28B). The key difference: Merck & Co., Inc. is far larger — about 25.6× TKO Group Holdings Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | TKO | |
|---|---|---|
Market Cap | $366.28B | $14.28B |
Sector | Health | Technology |
52-Week High | $156.43 | $224.96 |
52-Week Low | $77.60 | $176.49 |
Enterprise Value | $413.04B | $18.64B |
Dividend Yield | 2.29% | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
TKO trades at $195.32, up 5.01% today, with a bullish technical outlook and strong analyst support. Recent Q2 2026 earnings showed revenue growth to $1.5 billion, though EPS missed expectations. The company benefits from media rights strength in UFC and WWE, with revenue projected to rise to $5.3 billion in 2026. Positive sentiment is driven by dividend declarations and conference participation.
The outlook is positive with a consensus price target of $228.17, implying 17% upside. Risks include earnings volatility and competitive pressures in sports entertainment. Institutional ownership trends and bullish analyst ratings (89% buy) support a favorable investment case, but investors should monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
